Pretransplant absolute monocyte count in peripheral blood predicts posttransplant tumor prognosis in patients undergoing liver transplantation for hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 13, Issue 3, 2014, Pages 250-258

  Kim, Young Kyu ^a,b   Kim, Seong Hoon ^a   Lee, Seung Duk ^a   Lee, Soon ae ^a   Park, Sang Jae ^a  

^a National Cancer Center   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Monocyte count; Recurrence; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; FLUORODEOXYGLUCOSE F 18; HEPATITIS B ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ABSOLUTE MONOCYTE COUNT IN PERIPHERAL BLOOD; ADULT; ARTICLE; BLOOD; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILAN CRITERIA; MONOCYTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE EVALUATION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; ADVERSE EFFECTS; AREA UNDER THE CURVE; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CHI SQUARE DISTRIBUTION; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84904044347     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(14)60251-4     Document Type: Article

References (22)

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
2. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33: 1080-1086.
3. Schwartz ME, D'Amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? Eur J Surg Oncol 2008;34:256-262.
4. Bruckner HW, Lavin PT, Plaxe SC, Storch JA, Livstone EM. Absolute granulocyte, lymphocyte, and moncyte counts. Useful determinants of prognosis for patients with metastatic cancer of the stomach. JAMA 1982;247:1004-1006.
5. Elias EG, Leuchten JM, Buda BS, Brown SD. Prognostic value of initial mononucleated cell percentages in patients with epidermoid carcinoma of the head and neck. Am J Surg 1986;152:487-490.
6. Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Tominaga M, et al. Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. J Gastrointest Surg 2007;11:596-602.
7. Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery 2006;139:755-764.
8. Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 2003;39:215-221.
9. Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, et al. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int 2013;26:50-60.
10. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-1092.
11. Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002;6:224-232.
12. Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009;9:592-600.
13. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-1660.
14. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78.
15. Kuang DM, Peng C, Zhao Q, Wu Y, Zhu LY, Wang J, et al. Tumor-activated monocytes promote expansion of IL-17- producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol 2010;185:1544-1549.
16. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010;51:154-164.
17. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003;52:155-161.
18. An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2012;18:1406-1414.
19. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005;103:1856-1864.
20. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007;27:1091- 1097.
21. Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, Mahadev S, et al. Negative impact of neutrophillymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-151.
22. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009;50:682-687.